<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Bendamustine and <z:chebi fb="1" ids="16040">cytosine</z:chebi> <z:chebi fb="0" ids="22601">arabinoside</z:chebi> (ara-c) are commonly used cytotoxic agents with unique mechanisms of action </plain></SENT>
<SENT sid="1" pm="."><plain>We have previously reported a striking additive cytotoxic effect of the consecutive combination of bendamustine and ara-c in mantle cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MCL</z:e>) cell lines </plain></SENT>
<SENT sid="2" pm="."><plain>In the present study, cell lines of follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (DOHH-2), <z:hpo ids='HP_0005550'>chronic lymphocytic leukemia</z:hpo>/<z:hpo ids='HP_0002665'>lymphoma</z:hpo> (EHEB), diffuse large B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (SU-DHL-4), T-cell <z:hpo ids='HP_0001909'>leukemia</z:hpo>/<z:hpo ids='HP_0002665'>lymphoma</z:hpo> (JURKAT and KARPAS-299) and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MCL</z:e> (JEKO-1 and GRANTA-519) were exposed to the two single drugs or the drugs combined, given simultaneously and consecutively </plain></SENT>
<SENT sid="3" pm="."><plain>Peripheral blood <z:hpo ids='HP_0005550'>chronic lymphocytic leukemia</z:hpo> (CLL) B-cells from five patients were also analyzed </plain></SENT>
<SENT sid="4" pm="."><plain><z:mpath ids='MPATH_3'>Apoptosis</z:mpath>, cell proliferation/metabolic activity and <z:hpo ids='HP_0001427'>mitochondrial</z:hpo> damage were evaluated </plain></SENT>
<SENT sid="5" pm="."><plain>The combination index (CI) was used to assess synergy between the drugs </plain></SENT>
<SENT sid="6" pm="."><plain>Bendamustine exhibited a relevant cytotoxic effect that was dose- and time-dependent, except for SU-DHL-4 and T-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> cells </plain></SENT>
<SENT sid="7" pm="."><plain>The addition of ara-c after bendamustine significantly potentiated the single-drug cytotoxic effect of bendamustine on <z:hpo ids='HP_0000001'>all</z:hpo> cell lines, including 17p - CLL B-cells, JURKAT and SU-DHL-4, the latter presenting the highest synergism (CI &lt;â€‰0.01) </plain></SENT>
<SENT sid="8" pm="."><plain>Bendamustine and ara-c are highly synergistic on T- and B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> cells and cell lines, similar to <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MCL</z:e>, overcoming resistance to the single agents </plain></SENT>
</text></document>